Invesco Biotechnology & Genome ETF (NY:PBE)

Both ETFs offer investors a way to profit from advances in medicine, but a closer look reveals a clear winner.

Topics ETFs

Big Pharma vs. Breakthrough Biotech: Which ETF Has More Upside for Investors? ↗

October 22, 2026

Which Healthcare ETF Is the Better Buy: Fidelity’s Broad FHLC or Invesco’s Biotech-Focused PBE? ↗

Topics ETFs

October 11, 2026

One offers broad diversification at 0.08% cost, while the other targets concentrated biotech growth with higher volatility.

Topics ETFs

MannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales Matters ↗

November 05, 2025

Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion ↗

October 29, 2025

Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease ↗

September 23, 2025

PBE vs. RSPH: Is a Biotech ETF or Equal-Weight Healthcare ETF the Better Choice for Investors? ↗

September 15, 2026

PBE offers higher income and stronger returns, while RSPH provides broader diversification with lower costs and drawdown risk.

Broad diversification and lower costs favor iShares, but Invesco's concentrated biotech bet delivered 47% returns in one year—at the cost of steeper drawdowns.

Topics ETFs

iShares' IYH or Invesco's PBE: Which Healthcare ETF Is the Better Long-Term Buy? ↗

September 09, 2026

IHE delivered 53.2% returns over one year with lower volatility and a 0.37% expense ratio, while PBE's quantitative biotech strategy carries higher risk.

Topics ETFs

Pharma ETF or Biotech ETF: Which Matches Your Investing Mindset? ↗

August 21, 2026

PBE concentrates on 31 companies and offers a higher dividend yield, while IBBQ spreads risk across 251 holdings at a fraction of the cost.

Topics ETFs

IBBQ vs. PBE: Which Biotech ETF Is the Better Buy? ↗

August 21, 2026

VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style? ↗

Topics ETFs

August 12, 2026

VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better.

XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist? ↗

Topics ETFs

August 01, 2026

PBE surged 41% in one year but endured a 35% drawdown, while XLV's diversified approach delivered steadier gains with half the volatility.

PBE delivered the better return over the past year, but has experienced greater historical volatility. VHT's more diversified portfolio and rock-bottom fees offer investors a steadier, lower-cost...

Topics ETFs

VHT vs. PBE: Which Health Care ETF Is the Better Buy? ↗

July 30, 2026

The U.S. FDA approved an update to the prescribing information for Afrezza inhalation powder to treat adults with diabetes mellitus.

Topics ETFs

Why Did MNKD Stock Jump Over 7% In Pre-Market Today? ↗

January 26, 2026

The U.S. pharmaceutical industry is at the center of a policy maelstrom.

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗

September 29, 2025

Via Benzinga

Topics ETFs

3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential ↗

February 19, 2024

Biotech stocks, namely those involved with gene editing, have been explosive and could see higher highs with strong catalysts.

Via InvestorPlace

Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention ↗

April 13, 2023

U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval of...

Via Benzinga

Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules ↗

April 13, 2023

A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug.

Via Benzinga

New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications ↗

April 12, 2023

New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this...

Via Benzinga

Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead ↗

April 11, 2023

In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating...

Via Benzinga

FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits ↗

April 06, 2023

Via Benzinga

US Judge Weighs Nationwide Ban On Abortion Pills ↗

March 16, 2023

U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is...

Via Benzinga

FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug' ↗

March 01, 2023

Via Benzinga

7 Best Biotech Stocks to Buy in July 2022 ↗

July 08, 2022

The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict.

Via InvestorPlace

Biotech ETFs That Outperformed Last Week ↗

December 20, 2021

Though the broad U.S. market saw a tumultuous ride last week with most of the sectors in red, biotechnology was the biggest gainer.

Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon...

A Comprehensive Guide To Genomic ETFs ↗

July 11, 2021

Here is a look at five ETFs with large exposure to Biogen shares.

5 Top ETFs With Exposure To Biogen ↗

June 07, 2021

For the first time in 18 years, there was a new treatment for Alzheimer’s Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that...

5 Top ETFs With Exposure To Biogen ↗

June 07, 2021

Via Benzinga

3 Biotech Stocks Wall Street Predicts Will Rally By 45% Or More ↗

May 30, 2021

Wall Street analysts expect the biotech industry to grow significantly soon, with the biotech stocks Organogenesis (ORGO), BioDelivery Sciences (BDSI) and Champions Oncology (CSBR) gaining more...